| Trial ID: | L6271 |
| Source ID: | NCT04810507
|
| Associated Drug: |
Anagliptin Bid Treatment
|
| Title: |
MAGE of Anagliptin Compared With Sitagliptin With Type 2 Diabetes Mellitus
|
| Acronym: |
ACACIA
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes
|
| Interventions: |
DRUG: Anagliptin BID Treatment
|
| Outcome Measures: |
Primary: Effect of Improving Glycemic Variability, Mean amplitude of glycemic excursion (MAGE), 3 days after 12 weeks treatment | Secondary: Average nighttime (18:00~07:59) blood glucose change after 12 weeks compared to baseline, after 12 weeks compared to baseline in the test group and the control group, after 12 weeks treatment
|
| Sponsor/Collaborators: |
Sponsor: JW Pharmaceutical
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
89
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2018-11-09
|
| Completion Date: |
2021-01-05
|
| Results First Posted: |
|
| Last Update Posted: |
2021-03-24
|
| Locations: |
Kangdong Sacred Heart Hospital, Seoul, Korea, Republic of
|
| URL: |
https://clinicaltrials.gov/show/NCT04810507
|
